The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with high GI and pulmonary involvement.

On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...

Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for ...

The PHQ-8 is an important scoring system used to examine depressive symptoms and their severity. Findings from an analysis of the Patient Health Questionnaire (PHQ-8) did not demonstrate substantial ...

Sclerosing bone dysplasias encompass abnormalities in bone density, divided into hereditary and nonhereditary forms. Primarily diagnosed through radiography, they are often incidental findings. Among ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, today announced significant enhancements to ...

University of Virginia School of Medicine researchers have uncovered a possible way to prevent the dangerous hardening of skin and organs in people with systemic scleroderma, a rare autoimmune disease ...

Background Systemic sclerosis, also known as scleroderma, is a complex, multi-organ disease which causes substantial and progressive fibrosis of the skin and internal organs, including the heart and ...

A study from Sweden’s Uppsala University discovered a link between microplastics and multiple sclerosis (MS). The research, published in the journal Environmental International, discovered that ...

Sanofi SAN-0.86%decrease; red down pointing triangle shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key ...